Ovarian Serous Adenocarcinoma

Dato-DXd showed marked antitumor activity in a treatment-resistant LGSOC PDX model. Clinical evaluation in patients with recurrent LGSOC is warranted.

P1/2, N=4, Not yet recruiting, Verastem Inc.

P2, N=120, Not yet recruiting, Shandong University

Experimental perturbation in mucinous ovarian cancer models produced concordant reciprocal changes in lactate and malignant phenotypes, extending this triangle biologically. This integrative MR framework delineates histotype-specific metabolic drivers and links them to actionable targets, providing a roadmap from genetic prioritization to mechanistic and translational validation.

P2, N=37, Active, not recruiting, University of Oklahoma | Recruiting --> Active, not recruiting

Our findings emphasize that when imaging or cytology suggests multiorigin components, clinicians should pursue thorough intraoperative exploration, multisite biopsies, and prophylactic appendectomy. Ultimately, the management of such patients requires highly individualized surgical and chemotherapeutic strategies that account for the divergent biological behaviors and therapeutic sensitivities of both HGSOC and well-differentiated appendiceal mucinous adenocarcinoma to optimize oncological outcomes.

CA125 in low-grade serous ovarian cancer correlates with disease stage, reflects treatment response, and shows prognostic relevance for progression-free survival at pre-defined clinical time points. It may support recurrence detection but should not be used as a stand-alone marker.

She was treated with a methylprednisolone taper, budesonide and infliximab, resulting in resolution of symptoms. In this case, colitis was successfully managed with corticosteroids and infliximab, allowing for safe re-challenge at a reduced dose. This case highlights the importance of recognizing and managing rare toxicities associated with antibody-drug conjugates to optimize their safe use in ovarian cancer treatment.

P1, N=103, Active, not recruiting, BeiGene | Recruiting --> Active, not recruiting | N=258 --> 103 | Trial completion date: Jul 2028 --> Aug 2026 | Trial primary completion date: Apr 2028 --> Aug 2026

MUC4, particularly when combined with WT1, is a promising immunohistochemical marker that may support accurate determination of tumor origin and may aid in diagnosis in challenging cases. Further validation in larger cohorts is warranted.

MSBM enables robust HRD evaluation from a whole-exome sequencing assay. Olaparib monotherapy demonstrated clinical benefit for first-line maintenance in HRD-positive ovarian cancer without bevacizumab.

An equation based on five genes (ARID1A, NOTCH3, CSMD3, ELP4, and BARD1) showed strong predictive performance for olaparib response (area under the curve = 0.91). Collectively, these findings indicate that the CNV status of EV-DNA may serve as a non-invasive companion biomarker for patient stratification and therapeutic monitoring in HGSOC.